Verition Fund Management
TNGX icon

Verition Fund Management’s Tango Therapeutics TNGX Stock Holding History

Verition Fund Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-121,781
Closed -$1.08M – 3522
2025
Q4 		$1.08M Buy
121,781
+97,029
+392% +$836K ﹤0.01% 2100
2025
Q3 		$208K Buy
+24,752
New +$168K ﹤0.01% 3466
2025
Q1 		– Sell
-81,045
Closed -$250K – 3713
2024
Q4 		$250K Buy
81,045
+49,025
+153% +$228K ﹤0.01% 2865
2024
Q3 		$247K Buy
+32,020
New +$306K ﹤0.01% 2755
2023
Q4 		– Sell
-23,600
Closed -$266K – 2683
2023
Q3 		$266K Buy
+23,600
New +$144K ﹤0.01% 1812
2022
Q4 		– Sell
-12,449
Closed -$45K – 2727
2022
Q3 		$45K Hold
12,449
– – ﹤0.01% 2700
2022
Q2 		$56K Buy
+12,449
New +$75.4K ﹤0.01% 2135

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Verition Fund Management's TNGX Position: Q1 2026 in Review

Verition Fund Management sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 121,781 shares — an estimated $1.08M sold.

Verition Fund Management first reported a position in TNGX in Q2 2022 and held it in 7 quarters. The position peaked at $1.08M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Verition Fund Management reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 121,781 Tango Therapeutics shares in Q1 2026, an estimated $1.08M.
  • Verition Fund Management first reported a position in Tango Therapeutics in Q2 2022 and held it in 7 quarters.
  • Verition Fund Management's Tango Therapeutics position peaked at $1.08M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.